Jump to content

Pyrazolam

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by 193.242.143.183 (talk) at 22:40, 21 September 2014. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Pyrazolam
Clinical data
Routes of
administration
Oral, Sublingual, rectal
Legal status
Legal status
  • In general: legal
Pharmacokinetic data
Elimination half-life17 hours
Identifiers
  • 8-bromo-1-methyl-6-(pyridin-2-yl)-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
CAS Number
PubChem CID
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC16H12BrN5
Molar mass354.204 g/mol g·mol−1
3D model (JSmol)
  • CC1=NN=C2CN=C(C3=NC=CC=C3)C3=CC(Br)=CC=C3N12
  • InChI=1S/C16H12BrN5/c1-10-20-21-15-9-19-16(13-4-2-3-7-18-13)12-8-11(17)5-6-14(12)22(10)15/h2-8H,9H2,1H3
  • Key:BGRWSFIQQPVEML-UHFFFAOYSA-N

Pyrazolam is a benzodiazepine derivative originally developed by a team lead by Leo Sternbach at Hoffman-La Roche in the 1970s,[1] and subsequently "rediscovered" and sold as a research chemical starting in 2012.[2] It is mainly an anxiolytic, but it has also shown anticonvulsant and hypnotic effects at high doses. Pyrazolam has structural similarities to alprazolam[3] and bromazepam. Unlike other benzodiazepines pyrazolam does not appear to undergo metabolism, instead being excreted unchanged in the urine, no metabolites have been found in the urine of volunteers [4][5] and has anxiolytic activity 12x stronger than diazepam while causing little ataxia and sedation when used in its anxiolytic dose range. It is most selective for the α2 and α3 receptor subtypes[6]

Binding data (GABA):[citation needed]

α1 3.84±0.25
α2 1.31±0.19
α3 1.48±0.21
α5 3.72±0.32

References

  1. ^ US Patent 3954728 Preparation of triazolo benzodiazepines and novel compounds
  2. ^ Attention: This template ({{cite doi}}) is deprecated. To cite the publication identified by doi:10.1007/s11419-013-0187-4, please use {{cite journal}} (if it was published in a bona fide academic journal, otherwise {{cite report}} with |doi=10.1007/s11419-013-0187-4 instead.
  3. ^ 6-Phenyl-4H-s-triazolo[4,3-a][l,4]benzodiazepines Which Have Central Nervous System Depressant Activity J. Med. CHem Vol 14, No 11 Pages 1078-1081
  4. ^ http://www.uniklinik-freiburg.de/fileadmin/mediapool/08_institute/rechtsmedizin/pdf/Poster2013/Mossmann_DPHG2013.pdf>
  5. ^ Characterization of the designer benzodiazepine pyrazolam and its detectability in human serum and urine - Forensic Toxicology July 2013, Volume 31, Issue 2, pp 263-271
  6. ^ 6-Aryl-4H-s-triazolo[4,3-a][1,4]benzodiazepines. Influence of 1-substitution on pharmacological activity - J. Med. Chem., 1979, 22 (11), pp 1390–1398

Further reading

List of relevant reviews at Pubmed